{
    "root": "dab94c00-725f-4f4d-b1e3-21fd949fba3a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Mefenamic acid",
    "value": "20240815",
    "ingredients": [
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C RED NO. 3",
            "code": "PN2ZH5LOQY"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "MEFENAMIC ACID",
            "code": "367589PJ2C"
        }
    ],
    "indications": "carefully consider potential benefits risks mefenamic acid treatment options deciding mefenamic acid . lowest effective dose shortest duration consistent individual patient treatment goals ( ; gastrointestinal bleeding , ulceration , perforation ) . mefenamic acid indicated : relief mild moderate pain patients ≥ 14 years age , therapy exceed one week ( 7 days ) . treatment primary dysmenorrhea .",
    "contraindications": "carefully consider potential benefits risks mefenamic acid treatment options deciding mefenamic acid . lowest effective dose shortest duration consistent individual patient treatment goals ( ; gastrointestinal bleeding , ulceration , perforation ) . observing response initial therapy mefenamic acid , dose frequency adjusted suit individual patient 's needs . relief acute pain adults adolescents ≥14 years age , recommended dose 500 mg initial dose followed 250 mg every 6 hours needed , usually exceed one week . treatment primary dysmenorrhea , recommended dose 500 mg initial dose followed 250 mg every 6 hours , given orally , starting onset bleeding associated symptoms . indicate effective treatment initiated start menses necessary 2 3 days .",
    "warningsAndPrecautions": "mefenamic acid capsules usp 250 mg size ‘ 1 ’ yellow-yellow capsules ‘ ml ’ imprinted cap & ‘ 250 ’ imprinted body . ndc : 72162-2382-3 : 30 capsules bottle dispense tight container defined usp . storage store room temperature 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "mefenamic acid contraindicated following patients : known hypersensitivity ( e.g . , anaphylactic serious skin ) mefenamic acid components product ( ; anaphylactic , serious skin ) . history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids reported patients ( ; anaphylactic reaction , exacerbation asthma related aspirin sensitivity ) . setting coronary artery bypass graft ( cabg ) surgery ( ; cardiovascular thrombotic events ) .",
    "indications_original": "Carefully consider the potential benefits and risks of mefenamic acid and other treatment options before deciding to use mefenamic acid. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (\n       \n \n  see \n                     \n                        WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation\n                     ). \n      \n\n \n                  Mefenamic acid is indicated:\n                  \n                     For relief of mild to moderate pain in patients ≥ 14 years of age, when therapy will not exceed one week (7 days).\n                     For treatment of primary dysmenorrhea.",
    "contraindications_original": "Carefully consider the potential benefits and risks of mefenamic acid and other treatment options before deciding to use mefenamic acid. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals \n       \n \n  (see \n        \n  \n   WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation\n                     ). \n      \n\n \n                  \n                  After observing the response to initial therapy with mefenamic acid, the dose and frequency should be adjusted to suit an individual patient's needs.\n                  \n                  For the relief of acute pain in adults and adolescents ≥14 years of age, the recommended dose is 500 mg as an initial dose followed by 250 mg every 6 hours as needed, usually not to exceed one week.\n                  \n                  For the treatment of primary dysmenorrhea, the recommended dose is 500 mg as an initial dose followed by 250 mg every 6 hours, given orally, starting with the onset of bleeding  and associated symptoms. Clinical studies indicate that effective treatment can be initiated with the start of menses and should not be necessary for more than 2 to 3 days.",
    "warningsAndPrecautions_original": "Mefenamic Acid Capsules USP 250 mg are Size ‘1’ yellow-yellow capsules with ‘ML’ imprinted on the cap & ‘250’ imprinted on the body.\n                  NDC: 72162-2382-3: 30 Capsules in a BOTTLE\n                  Dispense in a tight container as defined in the USP.\n                  Storage\n                  Store at room temperature 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Mefenamic acid is contraindicated in the following patients:\n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to mefenamic acid or any components of the drug product (\n        \n  \n   see \n                        \n                           WARNINGS; Anaphylactic Reactions, Serious Skin Reactions)\n        \n  \n   . \n       \n \n  \n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients (\n        \n  \n   see \n                        \n                           \n                              WARNINGS;  Anaphylactic Reaction, Exacerbation of Asthma Related to Aspirin Sensitivity\n                           )\n         \n   \n    .\n                        \n                     \n                     In the setting of coronary artery bypass graft (CABG) surgery (see \n        \n  \n   \n                           WARNINGS; Cardiovascular  Thrombotic Events\n                        )\n        \n  \n   ."
}